Eiger BioPharmaceuticals Appoints Regulatory Expert and Industry Veteran Christine Murray, MS, RAC to its Board of Directors
"Ms. Murray has an extensive track record in leading teams through complex regulatory processes, interacting with regulatory agencies including
"I am very pleased to join Eiger's Board at this exciting point in the Company's evolution and look forward to working closely with the other Board members in supporting Eiger's management team to advance multiple, first-in-class, rare and ultra-rare disease programs to patients with unmet medical needs," said Ms. Murray.
Eiger is a late-stage biopharmaceutical company focused on the accelerated development and commercialization of a pipeline of targeted, first-in-class therapies for rare and ultra-rare diseases. The company's lead program is in Phase 3, developing lonafarnib, a first-in-class prenylation inhibitor for the treatment of Hepatitis Delta Virus (HDV) infection. The company is also preparing an NDA with plans to file in 2019 for lonafarnib in the treatment of Hutchinson-Gilford Progeria Syndrome (HGPS or Progeria) and Progeroid Laminopathies. For additional information about Eiger, please visit www.eigerbio.com.
View original content to download multimedia:http://www.prnewswire.com/news-releases/eiger-biopharmaceuticals-appoints-regulatory-expert-and-industry-veteran-christine-murray-ms-rac-to-its-board-of-directors-300773608.html